Traws Pharma (NASDAQ:TRAW) Issues Quarterly Earnings Results

Traws Pharma (NASDAQ:TRAW) released its earnings results on Monday. The company reported $95.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($7.00) by $102.66, Zacks reports.

Traws Pharma Price Performance

Shares of TRAW stock traded down $0.06 during trading on Monday, hitting $2.35. 8,290 shares of the company were exchanged, compared to its average volume of 155,791. The company has a market capitalization of $8.56 million, a price-to-earnings ratio of -0.02 and a beta of 1.42. The business’s 50-day moving average is $4.73. Traws Pharma has a twelve month low of $2.02 and a twelve month high of $24.75.

About Traws Pharma

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.